Compositions and methods for enhanced protein production in Bacillus cells

By integrating a prsA gene expression cassette at defined loci in Bacillus licheniformis, protein production is enhanced, addressing yield challenges and achieving significant improvements in protein output.

JP2024543466APending Publication Date: 2024-11-21DANISCO US INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024527833
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-16
Filing Date
2022-11-11
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Existing methods for optimizing protein production in Bacillus host cells, such as B. subtilis and B. licheniformis, face challenges in predicting and enhancing the yield of heterologous proteins, with small improvements being crucial for industrial applications.

Method used

Integration of a prsA gene expression cassette at defined loci in Bacillus licheniformis, specifically at the amyL or catH locus, with a prsA gene promoter and coding sequence, to enhance protein production.

Benefits of technology

The method results in increased production of proteins of interest, such as amylases, by up to 50% compared to control cells, demonstrating improved protein yield and productivity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543466000001
    Figure 2024543466000001
  • Figure 2024543466000002
    Figure 2024543466000002
  • Figure 2024543466000003
    Figure 2024543466000003
Patent Text Reader

Abstract

Certain embodiments of the present disclosure relate to recombinant Bacillus strains comprising an enhanced protein productivity phenotype, compositions and methods for constructing such recombinant Bacillus cells, etc. The recombinant Bacillus strains described herein are particularly useful for enhanced production of proteins of interest when grown / cultured / fermented under suitable conditions.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 63 / 279,813, filed November 16, 2021, which is incorporated by reference in its entirety.

[0002] The present disclosure relates generally to the fields of bacteriology, microbiology, genetics, molecular biology, enzymology, industrial protein production, etc. Certain embodiments of the present disclosure relate to recombinant Bacillus cells (strains) that comprise an enhanced protein productivity phenotype, compositions and methods for constructing such recombinant (modified) Bacillus cells, etc.

[0003] Sequence Listing Reference The contents of the electronic submission of the sequence listing text file entitled "NB42009-WO-PCT_SequenceListing.xml" was created on November 10, 2022, is 103KB in size, and is incorporated by reference herein in its entirety. [Background technology]

[0004] Gram-positive bacteria such as Bacillus subtilis, Bacillus licheniformis, and Bacillus amyloliquefaciens are frequently used as microbial factories to produce industrially relevant proteins due to their excellent fermentation properties and high yields (e.g., up to 25 grams per liter of culture; Van Dijl and Hecker, 2013). For example, host cells of Bacillus species are well known for their production of enzymes (e.g., amylase, cellulase, mannanase, pectate lyase, protease, pullulanase, etc.) required for food, textile, laundry applications, medical device cleaning, pharmaceutical industries, etc. These non-pathogenic Gram-positive bacteria produce proteins that are completely free of harmful by-products (e.g., lipopolysaccharides (LPS), also known as endotoxins), and thus have been awarded a “Qualified Presumption of Safety” (QPS) rating by the European Food Safety Authority (EFSA), and many of their products have earned a “Generally Recognized as Safe” (GRAS) rating from the US Food and Drug Administration (Olempska-Beer et al., 2006; Earl et al., 2008; Caspers et al., 2010).

[0005] Therefore, the production of proteins (e.g., enzymes, antibodies, receptors, etc.) via microbial host cells is of particular interest in the biotechnology field. Similarly, the optimization of Bacillus host cells to produce and secrete one or more proteins of interest is of great importance, especially in the context of industrial biotechnology, where small improvements in protein yields are of crucial importance when the proteins are to be industrially mass-produced. For example, the expression of many heterologous proteins remains unpredictable in terms of yield, etc. As described hereinafter, the present disclosure relates to a highly desirable and unmet need to obtain and construct Bacillus sp. cells (e.g., protein-producing host cells) with enhanced protein production capabilities. Summary of the Invention [Means for solving the problem]

[0006] As described hereinafter, certain aspects of the present disclosure relate to compositions and methods for designing and constructing recombinant (modified) microbial host cells, such as the recombinant Bacillus strains exemplified herein, which may be particularly useful for enhanced production of a protein of interest when cultured under suitable conditions. Accordingly, certain embodiments of the present disclosure provide, inter alia, one or more prsA gene expression cassettes, prsA gene promoter sequences, prsA gene coding sequences (open reading frames), control cells, recombinant cells, proteins of interest, expression constructs (cassettes) encoding proteins of interest, and the like, suitable for introduction and integration at one or more defined B. licheniformis loci.

[0007] In certain embodiments, the present disclosure provides a prsA gene expression cassette. In certain aspects, the prsA gene cassette comprises an upstream (5') prsA gene promoter sequence operably linked to a downstream (3') prsA gene coding sequence (CDS). In related aspects, the prsA gene cassette comprises a 2 nd In another related aspect, the present disclosure provides a two copy prsA gene cassette suitable for integration at a defined genomic locus of a desired host cell. nd In one particular embodiment, the prsA gene promoter sequence comprises at least 85% identity to SEQ ID NO:29 and / or the prsA gene CDS comprises at least 80% identity to SEQ ID NO:30.

[0008] Thus, certain other embodiments provide an introduced 2-amino acid sequence that produces a protein of interest and is integrated at a defined locus. nd The present invention relates to a recombinant B. licheniformis cell that contains an introduced bi-copy prsA gene cassette that produces a protein of interest (POI) and is integrated at a defined genomic locus (e.g., the B. licheniformis amyL locus). nd Recombinant B. licheniformis cells having a copy prsA gene cassette produce increased amounts of the POI compared to control B. licheniformis cells producing the same POI, where the control cells contain the same prsA gene cassette integrated at the catH locus, or the control cells contain a non-integrated copy of the same prsA gene cassette. In certain embodiments, the protein of interest (POI) is an enzyme.

[0009] Certain other embodiments generally involve constructing a B. licheniformis cell that produces a protein of interest (POI) and integrating an integrated 2'-terminal nucleotide sequence into the cell at a defined genomic locus (e.g., the B. licheniformis amyL locus). nd The present invention provides a method for producing a protein of interest in a B. licheniformis cell, comprising introducing into the cell a two copy prsA gene cassette and fermenting the recombinant cell under conditions suitable for production of the POI. Certain embodiments relate to recombinant B. licheniformis cells that produce an increased amount of a POI compared to a control B. licheniformis cell producing the same POI, where the control cell has the same two copy prsA gene cassette integrated at the catH locus. nd In certain other embodiments of the method, the protein of interest (POI) is an enzyme. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] A brief description of biological sequences SEQ ID NO:1 is a synthetic oligonucleotide (DNA) primer sequence 860.

[0011] SEQ ID NO:2 is the synthetic oligonucleotide primer sequence 861.

[0012] SEQ ID NO:3 is a synthetic oligonucleotide primer sequence 1636.

[0013] SEQ ID NO:4 is the synthetic oligonucleotide primer sequence 1637.

[0014] SEQ ID NO:5 is a synthetic oligonucleotide forward primer sequence.

[0015] SEQ ID NO:6 is a synthetic oligonucleotide reverse primer sequence.

[0016] SEQ ID NO:7 is a synthetic oligonucleotide forward primer sequence.

[0017] SEQ ID NO:8 is a synthetic oligonucleotide reverse primer sequence.

[0018] SEQ ID NO:9 is a synthetic oligonucleotide forward primer sequence.

[0019] SEQ ID NO:10 is a synthetic oligonucleotide reverse primer sequence.

[0020] SEQ ID NO:11 is a synthetic DNA editing template.

[0021] SEQ ID NO:12 is a sequence verified plasmid isolate designated "pRF1005."

[0022] SEQ ID NO:13 is the open reading frame (ORF) sequence of the B. licheniformis serA1 gene.

[0023] SEQ ID NO:14 is the ORF sequence of the B. licheniformis lysA gene.

[0024] SEQ ID NO:15 is the DNA sequence of the pBl.comK plasmid.

[0025] SEQ ID NO:16 is the DNA sequence of the ΔrghR2 allele.

[0026] SEQ ID NO:17 is a 1523 bp PCR product of the ΔrghR2 allele carrying a deletion of the rghR2 gene CDS except for the first 9 bp and the last 9 bp.

[0027] SEQ ID NO:18 is a 1922 bp PCR product of the intact rghR2 allele.

[0028] SEQ ID NO:19 is the DNA sequence of the ΔdltA-2 allele.

[0029] SEQ ID NO:20 is a 2067 bp PCR product of the ΔdltA-2 allele carrying a 700 bp deletion of the dltA-2 gene CDS.

[0030] SEQ ID NO:21 is the 2767 bp PCR product of the intact dltA-2 allele.

[0031] SEQ ID NO: 22 is the introduced (2 nd ) DNA sequence of the linear PCR product targeting the amyL locus for integration of the copy prsA cassette.

[0032] SEQ ID NO:23 is the DNA sequence of the upstream (5') homology arm to the amyL locus.

[0033] SEQ ID NO:24 is the DNA sequence of the catH promoter.

[0034] SEQ ID NO:25 is the DNA sequence encoding the CatH protein.

[0035] SEQ ID NO:26 is a DNA sequence encoding a dual terminator sequence consisting of the catH terminator of SEQ ID NO:27 operably linked to the spoVG terminator of SEQ ID NO:28.

[0036] SEQ ID NO:27 is the DNA sequence encoding the catH terminator.

[0037] SEQ ID NO:28 is the DNA sequence encoding the spoVG terminator.

[0038] SEQ ID NO:29 is the DNA sequence of the native B. licheniformis prsA promoter.

[0039] SEQ ID NO:30 is the ORF sequence encoding the native B. licheniformis PrsA protein.

[0040] SEQ ID NO:31 is the DNA sequence of the B. licheniformis amyL terminator.

[0041] SEQ ID NO:32 is the downstream (3') homology arm to the amyL locus.

[0042] SEQ ID NO: 33 is introduced (2 nd ) DNA sequence of the copy amyL integration cassette amyL::catH-prsAp-prsA.

[0043] SEQ ID NO: 34 is a 2698 bp sequence.

[0044] SEQ ID NO:35 is a 3562 bp sequence.

[0045] SEQ ID NO:36 is the DNA sequence encoding the reporter "amylase 1" (Amy1) protein.

[0046] SEQ ID NO:37 is the DNA sequence of the synthetic p3 promoter.

[0047] SEQ ID NO:38 is the DNA sequence of the modified aprE 5'-UTR of B. subtilis.

[0048] SEQ ID NO:39 is the DNA sequence encoding the B. licheniformis AmyL signal peptide.

[0049] SEQ ID NO:40 is the DNA sequence of the B. licheniformis amyL transcription terminator.

[0050] SEQ ID NO:41 is the DNA sequence of the synthetic p2 promoter.

[0051] SEQ ID NO: 42 is the DNA sequence encoding the reporter "amylase 2" (Amy2) protein.

[0052] SEQ ID NO:43 is the amino acid sequence of the native B. licheniformis PrsA protein encoded by SEQ ID NO:30.

[0053] Detailed Description As described herein, certain embodiments of the present disclosure relate to compositions and methods for enhanced protein production in Bacillus (host) cells. In particular, certain aspects of the present disclosure provide recombinant Bacillus cells (strains) that are particularly useful for enhanced production of a protein of interest when the recombinant cells are grown / cultured / fermented. More particularly, as described hereinafter and further described in the Examples below, the Applicant has surprisingly demonstrated that two of the introduced prsA gene expression cassettes integrated at a defined B. licheniformis locus are capable of expressing a prsA gene that is expressed by a prsA gene. nd Recombinant B. licheniformis containing a copy of the prsA gene cassette integrated at the B. licheniformis catH locus was transformed with the same introduced 2 copies of the prsA gene cassette integrated at the B. licheniformis catH locus. ndIt has been observed that the prsA gene can produce increased amounts of a protein of interest compared to control B. licheniformis cells having a copy of the prsA gene. Accordingly, certain aspects of the present disclosure provide, inter alia, one or more prsA gene expression cassettes, prsA gene promoter sequences, prsA gene coding sequences (open reading frames), control cells, recombinant cells, expression constructs (cassettes) encoding a protein of interest, etc. suitable for introduction and integration into one or more predefined B. licheniformis loci.

[0054] I. Definition In consideration of the compositions and methods described herein, the following terms and phrases are defined. Terms not defined herein should be given the meanings commonly used in the art. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as commonly understood by those skilled in the art to which the compositions and methods of the present invention belong. Although any methods and materials similar or equivalent to those described herein can also be used to carry out or test the compositions and methods of the present invention, exemplary methods and materials are described below.

[0055] All publications and patents cited herein are hereby incorporated by reference in their entirety.

[0056] It is further noted that the claims may be drafted to exclude optional elements. As such, this statement is intended to serve as a prelude to the use of exclusive language, such as "solely," "only," "excluding," or "not including," in connection with the recitation of elements in the claim, or the use of a "negative" limitation or qualification thereof. An example of a disclaimer would be "wherein the recombinant cell produces an increased amount of a protein of interest relative to the control cell producing the same protein of interest, wherein the control cell comprises a non-integrating 2 nd The recombinant cells produce increased amounts of the target protein compared to control cells producing the same target protein, whereas the control cells do not contain a non-integrated copy of the prsA gene cassette. nd (including copies)".

[0057] As will be apparent to one of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has distinct components and features which may be readily separated or combined with any of the features of some of the other embodiments without departing from the scope or spirit of the compositions and methods described herein. Any described method may be carried out in the order of events recited or in any other order which is logically possible.

[0058] As used herein, the genus "Bacillus" includes all species within the genus "Bacillus" known to those of skill in the art, such as, for example, B. subtilis, B. licheniformis, B. lentus, B. brevis, B. stearothermophilus, B. alkalophilus, B. arginini ... us, B. amyloliquefaciens, B. clausii, B. halodurans, B. megaterium, B. coagulans, B. circulans, B. lautus, and B. thuringiensis. It is recognized that the genus Bacillus continues to undergo taxonomic reorganization. Thus, the genus is intended to include organisms such as species that have been reclassified, for example, but not limited to, "B. stearothermophilus," which is now referred to as "Geobacillus stearothermophilus."

[0059] As used herein, the term "recombinant" or "non-naturally occurring" refers to an organism, microorganism, cell, nucleic acid molecule, or vector that has at least one engineered genetic change or has been modified by the introduction of a heterologous nucleic acid molecule, or to a cell (e.g., a microbial cell) that has been modified so that the expression of a heterologous or endogenous nucleic acid molecule or gene can be controlled. Recombinant also refers to a cell that is derived from or is the descendant of a non-naturally occurring cell that has one or more such modifications. Genetic changes include, for example, modifications that introduce an expressible nucleic acid molecule that encodes a protein, addition, deletion, substitution of a nucleic acid molecule, or other functional changes to the genetic material of the cell. For example, recombinant cells can express genes or other nucleic acid molecules that are not found in the same or homologous form in a native (wild-type) cell (e.g., fusion or chimeric proteins), or can provide an altered expression pattern of an endogenous gene, such as being overexpressed, underexpressed, minimally expressed, or not expressed at all. "Recombination," "recombining," or producing a "recombinant" nucleic acid is generally the assembly of two or more nucleic acid fragments, which assembly gives rise to a chimeric gene.

[0060] As used herein, "nucleic acid" refers to nucleotide or polynucleotide sequences, and fragments or portions thereof, and DNA, cDNA and RNA of genomic or synthetic origin, which may represent either the sense or antisense strand, and may be double-stranded or single-stranded. It will be understood that, as a result of the degeneracy of the genetic code, many nucleotide sequences can encode a given protein. It is understood that polynucleotides (or nucleic acid molecules) as described herein include "genes," "vectors," and "plasmids."

[0061] Thus, the term "gene" refers to a polynucleotide that codes for a particular amino acid sequence, including all or part of a coding sequence for a protein, and may include regulatory (non-transcribed) DNA sequences, such as promoter sequences, that determine the conditions under which the gene is expressed. The transcribed region of a gene may include introns, untranslated regions (UTRs), including 5'-untranslated regions (UTRs) and 3'-UTRs, and coding sequences (CDSs).

[0062] As used herein, the term "coding sequence" (abbreviated "CDS") refers to a nucleotide sequence, which directly specifies the amino acid sequence of its (encoded) protein product. The boundaries of a coding sequence are generally determined by an open reading frame (hereinafter "ORF"), which usually begins with the ATG start codon. Coding sequences typically include DNA, cDNA, and recombinant nucleotide sequences.

[0063] The term "promoter" as used herein refers to a nucleic acid sequence capable of controlling the expression of a coding sequence or functional RNA. Generally, the coding sequence (CDS) is located 3' (downstream) of the promoter sequence. Promoters may be derived entirely from a native gene (e.g., the prsA gene promoter), or may be composed of different elements derived from different naturally occurring promoters, or may include synthetic nucleic acid segments. Those skilled in the art will appreciate that different promoters may direct the expression of a gene in different cell types, or at different developmental stages, or in response to different environmental or physiological conditions. The promoters that most frequently cause expression of a gene in most cell types are generally referred to as "constitutive promoters". Furthermore, it has been recognized that DNA fragments of different lengths may have the same promoter activity, since in most cases the exact boundaries of regulatory sequences are not completely clear.

[0064] As used herein, the plasmid designated "pRF879" refers to the pRF879 plasmid of SEQ ID NO: 78, as described in WO2021146411.

[0065] As used herein, the plasmid named "pZM221" refers to the pZM221 plasmid of SEQ ID NO: 84 described in WO2021146411.

[0066] As used herein, the plasmid designated "pRF1005" (SEQ ID NO: 12) is a Cas9 plasmid that targets the catH locus and contains the editing template of SEQ ID NO: 11.

[0067] As used herein, "wild-type (native) prsA" encodes "wild-type (native) PrsA protein."

[0068] As used herein, the wild-type (naturally occurring) Bacillus licheniformis "prsA gene promoter" comprises the DNA sequence set forth in SEQ ID NO:29.

[0069] As used herein, the wild-type B. licheniformis "PrsA gene coding (CDS)" comprises the open reading frame (ORF) set forth in SEQ ID NO: 30 and encodes the native PrsA protein. In certain embodiments, a functional PrsA protein comprises a "protein chaperone" function or activity.

[0070] In certain embodiments, the wild-type prsA gene CDS comprises about 80% or more (nucleotide) sequence identity to SEQ ID NO: 30. In other aspects, the wild-type prsA gene CDS comprises at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 30. In other embodiments, the wild-type prsA gene promoter comprises about 85% sequence identity to SEQ ID NO:29. In certain aspects, the wild-type prsA gene promoter comprises at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:29.

[0071] As used herein, when a Bacillus host cell of the present disclosure contains an endogenous (native) "prsA gene" (i.e., encoding a native PrsA protein), and a polynucleotide (e.g., an integrated expression cassette) encoding the native PrsA protein is introduced into the same Bacillus host cell, the introduced polynucleotide is referred to herein as a "second ( nd ) copy prsA gene.

[0072] As used herein, the phrase "2 nd "Copy prsA gene" refers to an introduced polynucleotide comprising a prsA gene CDS having at least 80% identity to the ORF of SEQ ID NO: 30. nd The copy prsA gene CDS can be expressed from a functional prsA gene promoter region that contains at least 85% identity to the prsA promoter region of SEQ ID NO: 29. In certain embodiments, the introduced 2 ndThe copied prsA gene comprises at least the upstream (5') prsA gene promoter sequence operably linked to the downstream (3') prsA gene CDS (eg, 5'-[prsA gene promoter]-[prsA gene CDS]-3').

[0073] As used herein, the B. licheniformis strain designated "BF140" contains a deletion of the serA1 gene (ΔserA1; SEQ ID NO: 13) and a deletion of the lysA gene (ΔlysA; SEQ ID NO: 14) and an introduced pBl.comK plasmid (SEQ ID NO: 15), as generally described in WO 2019 / 40412.

[0074] As used herein, the B. licheniformis strain designated "BF412" contains a deletion of serA1 (ΔserA1; SEQ ID NO: 13), a deletion of lysA (ΔlysA; SEQ ID NO: 14), an introduced pBl.comK plasmid (SEQ ID NO: 15), and a deleted rghR2 (ΔrghR2) allele, as generally described in WO 2021 / 146411.

[0075] As used herein, the B. licheniformis strain designated "BF772" contains a deletion of serA1 (ΔserA1; SEQ ID NO: 13), a deletion of lysA (ΔlysA; SEQ ID NO: 14), an introduced pBl.comK plasmid (SEQ ID NO: 15), a deleted rghR2 (ΔrghR2) allele, and a deleted dltA-2 (ΔdltA-2), as generally described in International Publication No. WO 2021 / 146411.

[0076] As used herein, the B. licheniformis strain designated "ZM1319" contains a deletion of serA1 (ΔserA1; SEQ ID NO:13), a deletion of lysA (ΔlysA; SEQ ID NO:14), an introduced pBl.comK plasmid (SEQ ID NO:15), a deleted rghR2 (ΔrghR2) allele, a deleted dltA-2 (ΔdltA-2), and an introduced (2 nd copy) (e.g., 5'-[prsA promoter]-prsA gene coding sequence (ORF)]-3').

[0077] As used herein, the B. licheniformis isolate designated "ZM1322" contains a deletion of serA1 (ΔserA1; SEQ ID NO: 13), a deletion of lysA (ΔlysA; SEQ ID NO: 14), an introduced pBl.comK plasmid (SEQ ID NO: 15), a deleted rghR2 (ΔrghR2) allele, a deleted dltA-2 (ΔdltA-2), and an introduced (2 nd copy) (e.g., 5'-[prsA promoter]-prsA gene coding (ORF)]-3').

[0078] As used herein, the B. licheniformis strain designated "ZM1325" contains a deletion of serA1 (ΔserA1; SEQ ID NO:13), a deletion of lysA (ΔlysA; SEQ ID NO:14), an introduced pBl.comK plasmid (SEQ ID NO:15), a deleted rghR2 (ΔrghR2) allele, a deleted dltA-2 (ΔdltA-2), and an introduced (2 nd copy) (e.g., 5'-[prsA promoter]-prsA gene coding sequence (ORF)]-3').

[0079] As used herein, the B. licheniformis isolate designated "BF613" contains a deletion of serA1 (ΔserA1; SEQ ID NO:13), a deletion of lysA (ΔlysA; SEQ ID NO:14), an introduced pBl.comK plasmid (SEQ ID NO:15), a deleted rghR2 (ΔrghR2) allele, a deleted dltA-2 (ΔdltA-2), and an introduced (2nd copy) of the prsA gene integrated at the catH locus (e.g., 5'-[prsA promoter]-prsA gene coding (ORF)]-3').

[0080] As used herein, B. licheniformis strain "LDN665" contains two copies of Amy1 and two copies of prsA integrated at the catH locus. nd and an amylase 1 (Amy1) reporter strain containing the p53A gene and the p53A gene.

[0081] As used herein, B. licheniformis strain "ZM1351" contains two copies of Amy1 and two copies of prsA integrated at the amyL locus. nd and an amylase 1 (Amy1) reporter strain containing the p53A gene and the p53A gene.

[0082] As used herein, B. licheniformis strain "WAAA57" is an amylase 2 (Amy2) reporter strain that contains two copies of Amy2 and a second copy of prsA integrated at the catH locus.

[0083] As used herein, B. licheniformis strain "WAAA197" is an amylase 2 (Amy2) reporter strain that contains two copies of Amy2 and a second copy of prsA integrated at the amyL locus.

[0084] As used herein, the term "Amylase 1" or "amylase 1" protein (abbreviated as "Amy1") refers to an amylase reporter protein, and DNA encoding the Amy1 reporter is set forth in SEQ ID NO:36.

[0085] As used herein, the term "Amylase 2" or "amylase 2" protein (abbreviated as "Amy2") refers to an amylase reporter protein, and DNA encoding the Amy2 reporter is set forth in SEQ ID NO:42.

[0086] As used herein, "host cell" refers to a cell that has the ability to act as a host or expression vehicle for a newly introduced DNA sequence. Thus, in certain embodiments of the present disclosure, the host cell is a Gram-positive (e.g., Bacillus sp.) cell or a Gram-negative E. coli cell.

[0087] As used herein, terms such as "modified" cells and "daughter" cells refer to recombinant cells that contain at least one genetic modification that is not present in the parent cell from which the modified cell is derived. In certain aspects, terms such as "unmodified" cells, "parent" cells and / or "control" cells may be used when compared to or in relation to modified cells of the present disclosure.

[0088] As used herein, when expression of a protein of interest (POI) in a control cell is compared to expression of the same POI in an "modified" cell, it will be understood that the "modified" and "modified" cells are grown / cultured / fermented under the same conditions (i.e., the same conditions of medium, temperature, pH, etc.). In certain embodiments, the increased amount of a protein of interest may be an endogenous Bacillus protein of interest (e.g., native protease, native amylase, etc.) or a heterologous protein of interest (e.g., recombinant protease, recombinant amylase, etc.) expressed in a recombinant Bacillus cell of the present disclosure. In certain aspects, the POI is secreted into the culture medium (broth).

[0089] As used herein, "increasing" protein production or "increased" protein production refers to an increased amount of a protein (e.g., a protein of interest) produced. The protein may be produced inside the host cell or secreted (or transported) into the culture medium. In certain embodiments, the protein of interest is produced (secreted) into the culture medium. Increased protein production may be detected, for example, as a higher maximum level of protein or enzyme activity (e.g., protease activity, amylase activity, pullulanase activity, cellulase activity, etc.) or as total extracellular protein produced, as compared to the parent cell.

[0090] As used herein, the terms "modification" and "genetic modification" are used interchangeably and include: (a) the introduction, substitution, or removal of one or more nucleotides in a gene (or its ORF), or the introduction, substitution, or removal of one or more nucleotides in a regulatory element required for the transcription or translation of a gene or its ORF; (b) gene disruption; (c) gene conversion; (d) gene deletion; (e) gene downregulation; (f) directed mutagenesis; and / or (g) random mutagenesis of any one or more genes disclosed herein.

[0091] As used herein, the term "expression" refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid molecule of the present disclosure. Expression can also refer to the translation of mRNA into a polypeptide. Thus, the term "expression" includes any process involved in the production of a polypeptide, including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

[0092] As used herein, the term "operably linked" refers to the association of nucleic acid sequences on a single nucleic acid fragment such that the function of one is affected by the other. For example, a promoter is operably linked to a coding sequence (e.g., an ORF) if it is capable of affecting the expression of that coding sequence (i.e., when the coding sequence is under the transcriptional control of the promoter). A coding sequence can be operably linked to a regulatory sequence in a sense or antisense orientation.

[0093] A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA encoding a secretory leader (i.e., signal peptide) is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. Enhancers, however, need not be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

[0094] As used herein, "a functional promoter sequence (or open reading frame thereof) controlling expression of a gene of interest linked to a gene of a protein coding sequence of interest" refers to a promoter sequence that controls the transcription and translation of the coding sequence in a Bacillus sp. cell. For example, in certain embodiments, the present disclosure is directed to a polynucleotide comprising a 5' promoter (or a 5' promoter region or tandem 5' promoters, etc.), where the promoter region is operably linked to a nucleic acid sequence (e.g., an ORF) that encodes a protein.

[0095] As used herein, "suitable regulatory sequences" refer to nucleotide sequences located upstream (5' non-coding sequences), within or downstream (3' non-coding sequences) of a coding sequence that influence the transcription, RNA processing or stability or translation of the associated coding sequence. Regulatory sequences can include promoters, translation leader sequences, RNA processing sites, effector binding sites and stem-loop structures.

[0096] As used herein, the term "introducing", when used in phrases such as "introducing at least one polynucleotide open reading frame (ORF), or a gene thereof, or a vector thereof, into a bacterial cell" or "introducing into a Bacillus cell", includes methods known in the art for introducing polynucleotides into a cell, including, but not limited to, protoplast fusion, natural or artificial transformation (e.g., calcium chloride, electroporation), transduction, transfection, conjugation, and the like.

[0097] As used herein, "transformed" or "transformation" refers to a cell that has been transformed by the use of recombinant DNA technology. Transformation generally occurs by inserting one or more nucleotide sequences (e.g., polynucleotides, ORFs, or genes) into a cell. The inserted nucleotide sequence may be a heterologous nucleotide sequence (i.e., a sequence that does not naturally occur in the cell being transformed). Thus, transformation generally refers to the introduction of exogenous DNA into a host cell such that the DNA is maintained as a chromosomal integrant or a self-replicating extrachromosomal vector.

[0098] As used herein, "transforming DNA," "transforming sequence," and "DNA construct" refer to DNA used to introduce a sequence into a host cell or organism. Transforming DNA is DNA used to introduce a sequence into a host cell or organism. This DNA can be generated in vitro by PCR or any other suitable technique. In some embodiments, the transforming DNA includes the incoming sequence, while in other embodiments, the transforming DNA further includes the incoming sequence flanked by homology boxes. In yet other embodiments, the transforming DNA includes other non-homologous sequences (i.e., stuffer sequences or flanking sequences) added to the ends. The ends can be closed such that the transforming DNA forms a closed circle, such as, for example, by insertion into a vector.

[0099] As used herein, "gene disruption" or "gene disruption" are used interchangeably and refer broadly to any genetic modification that substantially prevents a host cell from producing a functional gene product (e.g., protein).Thus, as used herein, gene disruption includes, but is not limited to, frameshift mutations, premature stop codons (i.e., functional protein is not produced), substitutions that eliminate or reduce the activity of protein internal deletions (functional protein is not produced), insertions that disrupt coding sequences, mutations that remove the operable link between the native promoter and the open reading frame required for transcription, and the like.

[0100] As used herein, "incoming sequence" refers to a DNA sequence that is introduced into a Bacillus sp. chromosome. In some embodiments, the incoming sequence is part of a DNA construct. In other embodiments, the incoming sequence encodes one or more proteins of interest. In some embodiments, the incoming sequence comprises a sequence that may or may not already be present in the genome of the cell to be transformed (i.e., it may be a homologous or non-homologous sequence). In some embodiments, the incoming sequence encodes one or more proteins of interest, genes and / or mutant or modified genes. In alternative embodiments, the incoming sequence encodes a functional wild-type gene or operon, a functional mutant gene or operon, or a non-functional gene or operon. In some embodiments, a non-functional sequence may be inserted into a gene to disrupt the function of the gene. In another embodiment, the incoming sequence comprises a selection marker. In yet another embodiment, the incoming sequence comprises two homology boxes.

[0101] As used herein, a "homology box" refers to a nucleic acid sequence that is homologous to a sequence in a host cell chromosome. More specifically, a homology box is an upstream or downstream region that has about 80-100% sequence identity, about 90-100% sequence identity, or about 95-100% sequence identity with the immediately adjacent coding region of a gene or part of a gene to be deleted, disrupted, inactivated, downregulated, etc., according to the present invention. These sequences direct where in the chromosome the DNA construct is integrated and direct what part of the chromosome is replaced by the incoming sequence. Without intending to limit the disclosure, a homology box can include from about 1 base pair (bp) to 200 kilobases (kb). In certain embodiments, a homology box includes from about 1 bp to 10.0 kb; 1 bp to 5.0 kb; 1 bp to 2.5 kb; 1 bp to 1.0 kb, and 0.25 kb to 2.5 kb. A homology box can also comprise about 10.0 kb, 5.0 kb, 2.5 kb, 2.0 kb, 1.5 kb, 1.0 kb, 0.5 kb, 0.25 kb, and 0.1 kb. In some embodiments, the 5' and 3' ends of the selectable marker are flanked by homology boxes, where the homology box comprises nucleic acid sequences that are immediately adjacent to the coding region of a gene.

[0102] As used herein, the term "selectable marker encoding nucleotide sequence" refers to a nucleotide sequence that can be expressed in a host cell and where expression of the selectable marker confers to cells containing the expressed gene the ability to grow in the presence of a corresponding selective agent or in the absence of an essential nutrient.

[0103] As used herein, the terms "selectable marker" and "selection marker" refer to a nucleic acid (e.g., a gene) that can be expressed in a host cell to facilitate the selection of those hosts that contain a vector. Examples of such selectable markers include, but are not limited to, antimicrobial agents. Thus, the term "selectable marker" refers to a gene that provides an indication that a host cell has taken up an incoming DNA of interest or that some other reaction has occurred. Generally, a selectable marker is a gene that confers antimicrobial resistance or a metabolic advantage to a host cell that allows cells containing foreign DNA to be distinguished from cells that have not received the foreign sequence during transformation.

[0104] An "present selectable marker" is a marker that is located on the chromosome of the microorganism being transformed. The present selectable marker encodes a different gene than the selectable marker on the transforming DNA construct. Selectable markers are well known to those of skill in the art. As noted above, markers include antimicrobial resistance markers (e.g., amplicons ... R , phleo R , spec R , kan R ,ery R , tet R , cmp R and neo R In some embodiments, the present invention provides a chloramphenicol resistance gene (e.g., a gene present on pC194, as well as a resistance gene present in the genome of Bacillus licheniformis). This resistance gene is particularly useful in the present invention and in embodiments involving chromosomal integration cassettes and chromosomal amplification of integration plasmids. Other markers useful herein include, but are not limited to, auxotrophic markers such as serine (e.g., serA), lysine (e.g., lysA), tryptophan, and detectable markers (e.g., β-galactosidase).

[0105] As used herein, a host cell "genome," a bacterial (host) cell "genome," or a Bacillus sp. (host) cell "genome" includes chromosomal genes and extrachromosomal genes.

[0106] As used herein, the terms "plasmid," "vector," and "cassette" refer to extrachromosomal elements that typically carry genes that are not part of the central metabolism of a cell and are usually in the form of circular, double-stranded DNA molecules. Such elements may be linear or circular, single-stranded or double-stranded, autonomously replicating sequences of DNA or RNA, genome-integrating sequences, phages, or nucleotide sequences from any source in which multiple nucleotide sequences have been joined or recombined into a unique structure that can introduce into a cell a promoter fragment and a DNA sequence for a selected gene product along with appropriate 3' untranslated sequences.

[0107] As used herein, the term "plasmid" refers to a circular, double-stranded (ds) DNA construct that is used as a cloning vector and forms an extrachromosomal, self-replicating genetic element in many bacteria and some eukaryotes. In some embodiments, the plasmid becomes integrated into the genome of the host cell, and in some embodiments, the plasmid is present in the parent cell and lost in the daughter cells.

[0108] As used herein, a "transformation cassette" refers to a specific vector that contains a gene (or its ORF) and has elements in addition to a foreign gene that facilitate transformation of a particular host cell.

[0109] As used herein, the term "vector" refers to any nucleic acid that can replicate (multiply) in a cell and can carry new genes or DNA segments into the cell. Thus, the term refers to a nucleic acid construct designed for transport between various host cells. Vectors include viruses, bacteriophages, proviruses, plasmids, phagemids, transposons, which are "episomal" (i.e., they can replicate autonomously or be integrated into the chromosomes of the host organism), as well as artificial chromosomes, such as YACs (yeast artificial chromosomes), BACs (bacterial artificial chromosomes), and PLACs (plant artificial chromosomes).

[0110] "Expression vector" refers to a vector capable of incorporating and expressing heterologous DNA in a cell. Many prokaryotic and eukaryotic expression vectors are commercially available and known to those skilled in the art. The selection of an appropriate expression vector is within the knowledge of one of ordinary skill in the art.

[0111] As used herein, the terms "expression cassette" and "expression vector" refer to a nucleic acid construct (i.e., they are vectors or vector elements as described above) that is recombinantly or synthetically produced with a set of specific nucleic acid elements that allow transcription of a specific nucleic acid in a target cell. The recombinant expression cassette can be incorporated into a plasmid, a chromosome, mitochondrial DNA, plastid DNA, a virus, or a nucleic acid fragment. Typically, the recombinant expression cassette portion of an expression vector includes, among other sequences, a nucleic acid sequence to be transcribed and a promoter. In some embodiments, the DNA construct also includes a set of specific nucleic acid elements that allow transcription of a specific nucleic acid in a target cell. In certain embodiments, the DNA construct of the present disclosure includes a selectable marker and an inactivated chromosomal segment or gene segment or DNA segment as defined herein.

[0112] As used herein, a "targeting vector" is a vector that contains a polynucleotide sequence that is homologous to a region in a host cell chromosome into which the targeting vector is transformed and can drive homologous recombination at that region. For example, a targeting vector is used to introduce a mutation into a host cell chromosome by homologous recombination. In some embodiments, the targeting vector contains other non-homologous sequences (i.e., stuffer or flanking sequences), e.g., added to the ends. The ends can be closed such that the targeting vector forms a closed circle, e.g., by insertion into a vector. For example, in certain embodiments, parent B. licheniformis (host) cells are modified (e.g., transformed) by introducing one or more "targeting vectors" into them.

[0113] As used herein, the term "protein of interest" or "POI" refers to a protein of interest that is desired to be expressed in a recombinant host cell. In certain aspects, the modified host cell expresses an increased level of a POI as compared to a control cell expressing the same POI. Thus, a POI as used herein can be an enzyme, a substrate binding protein, a surfactant protein, a structural protein, a receptor protein, and the like. In certain aspects, the modified cells of the present disclosure produce an increased amount of a heterologous POI as compared to a control cell. In certain embodiments, the increased amount of POI produced by the modified cells is increased (or higher) by at least about 0.5%-1.0% as compared to a control cell.

[0114] The phrase "gene of interest" (abbreviated, "GOI") is used herein to refer to a nucleic acid (gene, ORF, polynucleotide) that encodes a protein of interest (POI). A "gene of interest (GOI)" that encodes a "protein of interest (POI)" may be a naturally occurring gene, a mutated gene, or a synthetic gene.

[0115] As used herein, the terms "polypeptide" and "protein" are used interchangeably and refer to polymers of any length that contain amino acid residues linked by peptide bonds. Conventional one-letter or three-letter codes for amino acid residues are used herein. Polypeptides may be linear or branched, may contain modified amino acids, and may be interrupted by non-amino acids. The term polypeptide also encompasses amino acid polymers that are modified, either naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling moiety. Also included within the scope of this definition are, for example, polypeptides that contain one or more analogs of an amino acid, including, for example, unnatural amino acids, and other modifications known in the art.

[0116] In certain embodiments, the genes of the present disclosure encode enzymes (e.g., acetyl esterase, aminopeptidase, amylase, arabinase, arabinofuranosidase, carbonic anhydrase, carboxypeptidase, catalase, cellulase, chitinase, chymosin, cutinase, deoxyribonuclease, epimerase, esterase, α-galactosidase, β-galactosidase, α-glucanase, glucan lysase, lysase), endo-β-glucanase, glucoamylase, glucose oxidase, α-glucosidase, β-glucosidase, glucuronidase, glycosyl hydrolase, hemicellulase, hexose oxidase, hydrolase, invertase, isomerase, laccase, lipase, lyase, mannosidase, oxidase, oxidoreductase, pectate lyase, pectin acetyl esterase, pectin depolymerase, pectin methyl esterase, pectin degrading enzyme, perhydrolase, polyol oxidase, peroxidase, phenol oxidase, phytase, polygalacturonase, protease, peptidase, rhamno-galacturonase, ribonuclease, transferase, transport protein, transglutaminase, xylanase, hexose oxidase, and combinations thereof.

[0117] As used herein, a "variant" polypeptide refers to a polypeptide derived from a parent (or reference) polypeptide by one or more amino acid substitutions, additions, or deletions, typically by recombinant DNA techniques. A variant polypeptide may differ from a parent polypeptide by a small number of amino acid residues and may be defined by the level of primary amino acid sequence homology / identity with the parent (reference) polypeptide.

[0118] Preferably, a variant polypeptide has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% amino acid sequence identity with a parent (reference) polypeptide sequence. As used herein, a "variant" polynucleotide refers to a polynucleotide that encodes a variant polypeptide, which has a particular degree of sequence homology / identity with a parent polynucleotide or hybridizes to a parent polynucleotide (or its complement) under stringent hybridization conditions. Preferably, the variant nucleotides have at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% nucleotide sequence identity to the parent (reference) polynucleotide sequence.

[0119] As used herein, the term "mutation" refers to any change or alteration in a nucleic acid sequence. There are several types of mutations, including point mutations, deletion mutations, silent mutations, frameshift mutations, splicing mutations, etc. Mutations can be made specifically (e.g., by site-directed mutagenesis) or randomly (e.g., by chemical agents, repair minus passaging through bacterial strains).

[0120] As used herein, in reference to a polypeptide or sequence thereof, the term "substitution" refers to the replacement (ie, substitution) of one amino acid with another.

[0121] As defined herein, "endogenous gene" refers to a gene that is present in its natural location in the genome of an organism.

[0122] As defined herein, a "heterologous" gene, "non-endogenous" gene or "foreign" gene refers to a gene (or ORF) that is not normally found in the host organism, but which has been introduced into the host organism by gene transfer. As used herein, the term "foreign" gene(s) includes a native gene (or ORF) inserted into a non-native organism and / or a chimeric gene inserted into a native or non-native organism.

[0123] As defined herein, a "heterologous control sequence" refers to a gene expression control sequence (e.g., a promoter or enhancer) that does not function in nature to regulate (control) the expression of a gene of interest. Generally, heterologous nucleic acid sequences are not endogenous (natural) to the cell or part of the genome in which they are present, but have been added to the cell by infection, transfection, transformation, microinjection, electroporation, etc. A "heterologous" nucleic acid construct may contain a control sequence / DNA coding (ORF) sequence combination that is the same or different from the control sequence / DNA coding sequence combination found in the native host cell.

[0124] As used herein, the terms "signal sequence" and "signal peptide" refer to a sequence of amino acid residues that may be involved in the secretion or direct transport of a mature protein or a precursor form of a protein. A signal sequence is generally located at the N-terminus of a precursor or mature protein sequence. A signal sequence may be endogenous or foreign. A signal sequence is not usually present in a mature protein. A signal sequence is generally cleaved from a protein by a signal peptidase after the protein has been transported.

[0125] The term "derived from" includes the terms "originating from," "obtained from," "available from," and "made from," and generally indicates that one particular material or composition has characteristics that can be found its origin in another material or composition, or that can be described with reference to that other particular material or composition.

[0126] As used herein, the term "homology" refers to homologous polynucleotides or homologous polypeptides. When two or more polynucleotides or two or more polypeptides are homologous, this means that the homologous polynucleotides or polypeptides have a "degree of identity" of at least 60%, more preferably at least 70%, even more preferably at least 85%, even more preferably at least 90%, more preferably at least 95%, and most preferably at least 98%. Whether two polynucleotide or polypeptide sequences have a sufficiently high degree of identity to be homologous as defined herein can be conveniently determined by aligning the two sequences using computer programs known in the art, such as "GAP" (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711) provided in the GCG program package (Needleman and Wunsch, 1970). GAP was used for DNA sequence comparison with the following settings: GAP creation penalty of 5.0 and GAP extension penalty of 0.3.

[0127] As used herein, the term "percent identity" refers to the level of nucleic acid or amino acid sequence identity between nucleic acid sequences encoding a polypeptide or between the amino acid sequences of a polypeptide when aligned using a sequence alignment program.

[0128] As used herein, the term "specific productivity" refers to the total amount of protein produced per cell per unit time over a given period of time.

[0129] As defined herein, the terms "purified," "isolated," or "enriched" refer to a biomolecule (e.g., a polypeptide or polynucleotide) that has been altered from its native state by separation from some or all of the naturally occurring components with which it is naturally associated. Such isolation or purification can be accomplished by separation techniques known in the art, such as ion exchange chromatography, affinity chromatography, hydrophobic separation, dialysis, protease treatment, ammonium sulfate precipitation or other protein salting out, centrifugation, size exclusion chromatography, filtration, microfiltration, gel electrophoresis, or separation by gradient to remove whole cells, cell debris, impurities, extraneous proteins, or enzymes that are not desired in the final composition. Purified or isolated biomolecule compositions can then be supplemented with components that provide additional benefits, such as activators, anti-inhibitors, desirable ions, pH adjusting compounds, or other enzymes or chemicals.

[0130] As used herein, "flanking sequence" refers to any sequence that is upstream or downstream of the sequence under consideration (e.g., in gene ABC, gene B is flanked by gene sequences A and C). In certain embodiments, the incoming sequence is flanked on both sides by homology boxes. In other embodiments, the incoming sequence and the homology box comprise a unit that is flanked on both sides by stuffer sequences. In some embodiments, the flanking sequences are present on only one side (3' or 5'), but in preferred embodiments, they are present on both sides of the sequence that they are flanking. The sequence of each homology box is homologous to a sequence in the Bacillus chromosome. These sequences direct where in the Bacillus chromosome the new construct will be integrated and which part of the Bacillus chromosome will be replaced by the incoming sequence. In other embodiments, the 5' and 3' ends of the selectable marker are flanked by polynucleotide sequences that comprise a portion of an inactivated chromosomal segment. In some embodiments, a flanking sequence is present on only one side (3' or 5'), while in other embodiments, it is present on both sides of the sequence it is flanked by.

[0131] II. Expression of a second copy of the PRSA gene from the AMYL locus enhances protein production The Bacillus subtilis prsA gene, which encodes the PrsA protein, was first defined by a non-lethal mutation that reduced the secretion of several exoproteins (Kontinen and Sarvas, 1988). The PrsA protein has been described to act as a chaperone and translocates across the cell membrane (Kontinen et al., 1993). WO 1994 / 19471 describes a Gram-positive bacterial expression system in which an introduced copy of the B. subtilis prsA gene coding sequence (CDS) is overexpressed (overproduced) using a variety of upstream promoters and sources, specifically specifying that PrsA protein overproduction means higher amounts than the wild type. Similarly, US Patent Publication No. 2010 / 0255534 describes overexpression of an introduced copy of the B. subtilis prsA gene CDS operably linked to a strong upstream promoter and containing one or more deleted or inactivated genes selected from abrB, dltA, dltB, dltC, dltD and dltE. The conclusion of these patent publications is that overexpression (overproduction) of prsA (PrsA) in a recombinant B. subtilis strain resulted in enhanced protein production compared to a B. subtilis strain that did not contain an introduced prsA gene overexpression cassette. More recently, WO 2021 / 146411 has described the overexpression of an introduced copy of the prsA gene (2 copies) integrated at the catH locus. nd We have described a recombinant B. licheniformis strain containing two copies of the nd The (copy) prsA gene contained the native prsA gene promoter region (e.g., 5'-[native prsA pro]-[native prsA ORF]-3') operably linked to the native prsA gene CDS. As described in this publication, the two copies of the prsA gene integrated at the catH locus were ndRecombinant B. licheniformis strains containing a duplicate prsA cassette produced increased amounts of the reporter protein compared to the control B. licheniformis strain.

[0132] As generally discussed above, the contrasting results of the constant and variable prsA gene expression levels indicate that the choice of promoter and locus is important. In particular, as shown in Table 1 below, Applicants expressed an amylase reporter protein (Table 1, column 2) and the two introduced nd Recombinant B. licheniformis strains containing the copied prsA gene cassette (Table 1, column 1) were screened. [Table 1]

[0133] For example, as shown in Table 1, 2 nd Protein productivity (amylase activity) of recombinant B. licheniformis strains expressing the copy prsA gene CDS under the control of its native promoter (i.e., 5'-[prsA pro]) was evaluated. nd The protein productivity of the recombinant strain expressing the copy prsA gene CDS was compared with that of the strain expressing the copy prsA gene CDS under the control of its native prsA promoter. As can be seen in Table 1, the protein productivity was 2 nd When compared to the productivity of strains expressing two copies of the prsA gene CDS under the control of a heterologous promoter, nd The copy number of prsA gene CDS expressed in the strain was reduced, further demonstrating that the choice of promoter region to drive expression of the prsA gene CDS is a non-trivial and easily predictable approach.

[0134] More specifically, as described hereinafter and in the Examples below, the Applicant has surprisingly found that an optimized and defined B. licheniformis locus integrated with the prsA expression cassette can be expressed in two introduced genomic DNA sequences. nd Recombinant B. licheniformis cells containing copies of the prsA expression cassette integrated at the B. licheniformis catH locus were transfected with the same transfected 2 nd It was observed that the prsA expression constructs were able to produce increased amounts of the reporter protein compared to control B. licheniformis cells containing a copy of the prsA gene. Accordingly, certain aspects of the present disclosure relate to prsA integration (expression) constructs specifically designed to target and integrate at one or more B. licheniformis genomic loci as described and contemplated herein.

[0135] More specifically, Examples 1 and 2 described below generally describe targeted prsA gene integration (2 nd Design and construction of plasmids suitable for nd This article describes the design and construction of recombinant B. licheniformis strains suitable for testing and screening for the introduction of two copies of the prsA (integration) cassette. In particular, as generally described in Examples 1 and 2, the two copies of the prsA (integration) cassette are introduced into the B. licheniformis strain. nd B. licheniformis cells were constructed containing a copy in which the prsA cassette was integrated at either the cstH locus or the amyL locus.

[0136] As described in Example 3, an expression cassette encoding a reporter protein (Amy1) was introduced into B. licheniformis strain BF613 (containing a prsA cassette integrated at the catH locus) and B. licheniformis strain ZM1325 (containing a prsA cassette integrated at the amyL locus). For example, as shown in Table 6 (Example 3), two Amy1-producing strains (LDN665 and ZM1351) were assayed for production of Amy1 using standard small-scale conditions, and the two Amy1-producing strains integrated at the catH locus were assayed for production of Amy1 using standard small-scale conditions. nd Compared with the strain (LDN665) containing a copy prsA cassette, two copies were integrated at the amyL locus. nd We demonstrate improved Amy1 production in a strain (ZM1351) carrying a duplicate prsA cassette.

[0137] An expression cassette encoding a second amylase reporter protein (Amy2) was introduced into B. licheniformis strains BF613 and ZM1325, as described further in Example 4. For example, as shown in Table 7 (Example 4), two Amy2-producing strains (WAAA57 and WAAA197) were assayed for production of Amy2 using standard small-scale conditions, revealing the presence of the 2A-amylase reporter protein integrated at the catH locus. nd Compared with the strain (WAAA57) containing a copy prsA cassette, two copies were integrated at the amyL locus. nd We demonstrate improved Amy2 production in a strain (WAAA197) containing a duplicate prsA cassette.

[0138] Accordingly, certain aspects of the present disclosure relate to a prsA gene coding sequence (CDS) that comprises sequence identity to the prsA gene CDS described herein, and / or a prsA gene promoter sequence that comprises homology to the prsA gene promoter sequence described herein. In certain related aspects, the prsA gene CDS encodes an active (functional) PrsA protein. For example, in certain embodiments, the prsA gene CDS encodes a PrsA protein that comprises at least about 50% identity to the mature PrsA amino acid sequence of SEQ ID NO: 43. In certain aspects, a PrsA protein that comprises at least 50% identity to the PrsA protein of SEQ ID NO: 43 is further defined as a functional or active PrsA protein.

[0139] III. Recombinant Polynucleotides and Molecular Biology As generally described herein above and hereinafter, certain aspects of the present disclosure relate to recombinant Bacillus strains producing proteins of interest. More specifically, as presented in the examples below, recombinant polynucleotides (vectors, expression cassettes, etc.), recombinant (modified) Bacillus strains, etc. are readily constructed using routine molecular biology and microbiology techniques and methods known to those of skill in the art. Thus, the present disclosure generally relies on routine techniques in the field of recombinant genetics. Basic texts disclosing the general methods used in the present disclosure include Sambrook et al., (2nd Edition, 1989); Kriegler (1990) and Ausubel et al., (1994). Similarly, those of skill in the art are well aware of suitable methods for introducing polynucleotide sequences into bacterial cells (e.g., E. coli, Bacilli, etc.).

[0140] Thus, in certain embodiments, the present disclosure provides, inter alia, an introduced 2D vector of a prsA expression cassette integrated at a defined locus. ndRecombinant Bacillus cells containing a copy of the prsA expression cassette that produces a protein of interest and is integrated at a defined locus. nd The present invention relates to compositions and methods for designing and constructing recombinant Bacillus cells containing copies of the desired protein, compositions and methods for producing increased amounts of a protein of interest, and the like.

[0141] In certain embodiments, the prsA gene coding sequence (CDS) comprises homology to the DNA sequence of SEQ ID NO: 30. For example, in certain aspects, the prsA gene CDS comprises at least about 50% identity to the prsA gene CDS of SEQ ID NO: 30. In certain aspects, the prsA gene CDS comprises at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% and up to 100% identity to the prsA gene CDS of SEQ ID NO: 30. In certain embodiments, the prsA gene CDS comprises 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 98%, 99% or 100% identity to the prsA gene CDS of SEQ ID NO:30.

[0142] In certain other aspects, the prsA gene promoter sequence comprises homology to the DNA sequence of SEQ ID NO: 29. For example, in certain aspects, the prsA gene promoter comprises at least about 50% identity to the prsA gene promoter of SEQ ID NO: 29. In certain aspects, the prsA gene promoter comprises at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% and up to 100% identity to the prsA gene promoter of SEQ ID NO: 29. In certain embodiments, the prsA gene promoter comprises 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 98%, 99% or 100% identity to the prsA gene promoter of SEQ ID NO: 29.

[0143] Thus, certain embodiments of the present disclosure provide a method for the preparation of a prsA gene CDS comprising: nd The invention relates to recombinant polynucleotides (e.g., plasmids, vectors, DNA constructs, etc.) encoding the copies, recombinant host cells, expression cassettes, compositions and methods for constructing recombinant polynucleotides, recombinant Bacillus host cells, and the like.

[0144] Thus, in certain embodiments, the polynucleotides (genes, vectors, plasmids, DNA elements, etc.) of the present disclosure may be genetically modified, including (a) introduction, substitution, or removal of one or more nucleotides in a gene (or its ORF), or introduction, substitution, or removal of one or more nucleotides in a gene or its ORF, (b) gene disruption, (c) gene conversion, (d) gene deletion, (e) gene downregulation (e.g., RNA interference), (f) directed mutagenesis and / or (g) random mutagenesis of any one or more genes disclosed herein. In certain embodiments, modified Bacillus cells of the present disclosure are constructed by increasing expression of a gene and / or decreasing (or eliminating) expression of a gene using methods well known in the art, such as insertion, disruption, substitution, or deletion. The portion of a gene to be modified or inactivated can be, for example, a coding region (CDS, ORF), or a regulatory (DNA) element required to express the coding region. An example of such a regulatory or control sequence may be a promoter sequence or a functional portion thereof (i.e., a portion sufficient to affect the expression of a nucleic acid sequence). Other control sequences for modification include, but are not limited to, leader sequences, propeptide sequences, signal sequences, transcription terminator sequences, transcription activator sequences, and the like.

[0145] Gene deletion techniques allow for partial or complete removal of a gene(s), thereby eliminating their expression or expressing a non-functional (or reduced activity) protein product. In such methods, deletion of a gene can be accomplished by homologous recombination using a plasmid that has been constructed to contain adjacent 5' and 3' regions flanking the gene. The adjacent 5' and 3' regions can be introduced into Bacillus cells, for example, on a temperature-sensitive plasmid, such as pE194, in association with a second selectable marker at a permissive temperature at which the plasmid can become established in the cell. The cells are then shifted to a non-permissive temperature to select for cells that have the plasmid integrated into the chromosome at one of the homologous flanking regions. Selection for integration of the plasmid is achieved by selection with the second selectable marker. After integration, recombination events at the second homologous flanking region are stimulated by shifting the cells to the permissive temperature for several generations without selection. The cells are plated to obtain single colonies, which are then tested for loss of both selectable markers. Thus, one of skill in the art may readily identify nucleotide regions within the coding sequence of a gene and / or the non-coding sequence of a gene that are suitable for complete or partial deletion, hi other embodiments, altered Bacillus cells of the present disclosure are constructed by introducing, substituting, or removing one or more nucleotides within a gene or a regulatory element required for their transcription or translation.

[0146] In certain embodiments, modified Bacillus cells are constructed by CRISPR-Cas9 editing. For example, wild-type genes encoding native proteins of interest (or functional variant proteins of interest) may be modified through CRISPR-Cas9 editing by nucleic acid-guided endonucleases that find their target DNA by binding to guide RNAs (e.g., Cas9) and Cpfl or guide DNAs (e.g., NgAgo), which recruit endonucleases to target sequences on DNA, where the endonucleases can generate single-strand or double-strand breaks in DNA. This targeted DNA break becomes a substrate for DNA repair and can recombine with the provided editing template (e.g., editing template for replacing native gene promoter sequence with a heterologous promoter). For example, a gene encoding a nucleic acid-guided endonuclease (for this purpose, Cas9 from S. pyogenes), or a codon-optimized gene encoding a Cas9 nuclease, is operably linked to a promoter active in a Bacillus cell and a terminator active in a Bacillus cell, thereby generating a Bacillus Cas9 expression cassette. Similarly, one or more target sites unique to a gene of interest are readily identified by one of skill in the art. For example, to construct a DNA construct encoding a gRNA directed to a target site within a gene of interest using Streptococcus pyogenes Cas9, a variable targeting domain (VT) would contain the nucleotides of the target site that are 5' of a protospacer adjacent motif (NGG) (PAM), which is fused to DNA encoding the Cas9 endonuclease recognition domain (CER) for S. pyogenes Cas9. Combination of the DNA encoding the VT domain with the DNA encoding the CER domain thereby generates DNA encoding the gRNA.Thus, a Bacillus expression cassette for a gRNA is generated by operably linking DNA encoding the gRNA to a promoter active in a Bacillus cell and a terminator active in a Bacillus cell.

[0147] In certain embodiments, the DNA break induced by the endonuclease is repaired / replaced with the incoming sequence. For example, to precisely repair the DNA break generated by the Cas9 expression cassette and gRNA expression cassette described above, a nucleotide editing template is provided so that the DNA repair mechanism of the cell can utilize the editing template. For example, about 500 bp 5' of the targeting gene can be fused to about 500 bp 3' of the targeting gene to generate an editing template, which is used by the Bacillus host's mechanism to repair the DNA break generated by RGEN. The Cas9 expression cassette, gRNA expression cassette and editing template can be delivered simultaneously to the cell using a number of different methods. The transformed cells are screened by PCR amplification of the target locus by amplifying the locus with forward and reverse primers. These primers can amplify the wild-type locus or the modified locus that has been edited by RGEN. These fragments are then sequenced using sequencing primers to identify edited colonies.

[0148] In other embodiments, modified Bacillus cells are constructed by random or directed mutagenesis using methods well known in the art, including, but not limited to, chemical mutagenesis and translocation. Genetic modification can be performed by subjecting parent cells to mutagenesis and screening for mutant cells in which expression of the gene has been altered. Mutagenesis, which may be directed or random, can be performed, for example, by using suitable physical or chemical mutagenizing agents, by using suitable oligonucleotides, or by subjecting the DNA sequence to PCR-generated mutagenesis. Furthermore, mutagenesis can be performed by any combination of these mutagenesis methods. Examples of physical or chemical mutagenizing agents suitable for the purposes of the present invention include ultraviolet (UV) irradiation, hydroxylamine, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), N-methyl-N'-nitrosoguanidine (NTG), O-methylhydroxylamine, nitrous acid, ethyl methanesulfonate (EMS), sodium bisulfite, formic acid, and nucleotide analogs. When such agents are used, mutagenesis is typically carried out by incubating the parent cells to be mutagenized in the presence of the mutagenizing agent of choice under suitable conditions, and selecting for mutant cells that show reduced or no expression of the gene.

[0149] WO 2003 / 083125 discloses methods for modifying Bacillus cells, such as the creation of Bacillus deletion strains and DNA constructs using PCR fusion to bypass E. coli. WO 2002 / 14490 discloses methods for modifying Bacillus cells, including (1) construction and transformation of an integrative plasmid (pComK), (2) random mutagenesis of coding, signal and propeptide sequences, (3) homologous recombination, (4) increasing transformation efficiency by adding non-homologous flanks to the transforming DNA, (5) optimizing double crossover integration, (6) site-directed mutagenesis, and (7) markerless deletion. Those skilled in the art are well aware of suitable methods for introducing polynucleotide sequences into bacterial cells (e.g., E. coli and Bacillus). Indeed, methods such as transformation, including protoplast transformation and mating, transduction, and protoplast fusion, are known and suitable for use in the present disclosure. Transformation methods are particularly preferred for introducing the DNA constructs of the present disclosure into host cells.

[0150] In addition to commonly used methods, in some embodiments, the host cell is directly transformed (i.e., no intermediate cells are used to amplify or otherwise process the DNA construct prior to introduction into the host cell). Introduction of the DNA construct into the host cell includes those physical and chemical methods known in the art for introducing DNA into a host cell without insertion into a plasmid or vector. Such methods include, but are not limited to, calcium chloride precipitation, electroporation, naked DNA, liposomes, and the like. In additional embodiments, the DNA construct is co-transformed with a plasmid without insertion into a plasmid. In further embodiments, the selection marker is deleted or substantially excised from the modified Bacillus strain by methods known in the art. In some embodiments, degradation of the vector from the host chromosome leaves flanking regions in the chromosome while removing the unique chromosomal region.

[0151] Promoters and promoter sequences, their open reading frames (ORFs) and / or their variant sequences for use in expressing genes in Bacillus cells are generally known to those skilled in the art. The promoter sequences of the present disclosure are generally selected so that they are functional in Bacillus cells, including but not limited to natural promoter sequences, synthetic promoter sequences, and / or combinations of these promoter sequences, which promoters (sequences) are operable / functional in Bacillus cells. Examples of synthetic (engineered) promoters capable of producing heterologous (foreign) proteins in Bacillus cells include, but are not limited to, the promoter systems described by Zhou et al. (2019), Wang et al. (2019) and Castillo-Hair et al. (2019). Other specific exemplary Bacillus promoter sequences include, but are not limited to, the B. subtilis alkaline protease (aprE) promoter, the B. subtilis alpha-amylase promoter, the B. amyloliquefaciens alpha-amylase promoter, the B. subtilis neutral protease (nprE) promoter, the mutant aprE promoter (WO 2001 / 51643), the B. licheniformis tuf promoter, the B. licheniformis citZ promoter, or any other functional promoter from a Bacillus sp. cell. In certain embodiments, a heterologous promoter is used to drive expression of the protein of interest or the prsA gene CDS. Methods for screening and generating promoter libraries with a wide range of activity (promoter strength) in Bacillus cells are described in WO 2003 / 089604.

[0152] IV. FERMENTATION OF BACILLUS CELLS FOR PRODUCTION OF DESIGN PROTEINS In certain embodiments, the present disclosure provides recombinant microbial cells that produce a protein of interest. More specifically, certain aspects generally relate to modified (recombinant) microbial cells that express a heterologous polynucleotide encoding a protein of interest. Accordingly, certain embodiments relate to growing, culturing, fermenting, etc., the microbial cells for the production of the protein of interest. Generally, fermentation methods well known in the art are used to ferment the microbial cells.

[0153] In some embodiments, cells are grown under batch or continuous fermentation conditions. Classical batch fermentation is a closed system where the composition of the medium is set at the beginning of the fermentation and is not changed during the fermentation. At the beginning of the fermentation, the medium is inoculated with the desired organism. In this method, fermentation is allowed to occur without adding any components to the system. Generally, batch fermentation is considered to be "batch" with respect to the addition of the carbon source, and factors such as pH and oxygen concentration are often controlled. The metabolite and biomass composition of a batch system changes constantly until the point at which the fermentation is stopped. Within a batch culture, cells progress through a static lag phase to a high growth log phase and finally to a stationary phase where the growth rate slows or stops. If left untreated, cells in the stationary phase will eventually die. Generally, cells in the log phase are responsible for the majority of the production of the product.

[0154] A suitable variation on the standard batch system is the "fed-batch fermentation" system. In this variation of the general batch system, substrate is added gradually as the fermentation progresses. Fed-batch systems are useful when catabolite repression is likely to inhibit the metabolism of the cells and when a limited amount of substrate in the medium is desired. Actual substrate concentration is difficult to measure in a fed-batch system and is therefore estimated based on changes in measurable factors such as pH, dissolved oxygen and partial pressure of exhaust gases such as CO2. Batch and fed-batch fermentation are common and well known in the art.

[0155] Continuous fermentation is an open system in which a defined fermentation medium is added continuously to a bioreactor and an equal amount of conditioned medium is simultaneously removed for processing. Continuous fermentation generally maintains the culture at a constant high density, with the cells primarily in logarithmic growth phase. Continuous fermentation allows for the adjustment of one or more factors that affect cell growth and / or product concentration. For example, in one embodiment, the limiting nutrient, such as the carbon or nitrogen source, is maintained at a constant ratio, and all other parameters can be adjusted. In other systems, a number of factors that affect growth can be continuously varied while the cell concentration, measured by the turbidity of the medium, is kept constant. Continuous systems attempt to maintain steady-state growth conditions. Thus, cell loss due to medium removal must be balanced against the cell growth rate during fermentation. Methods for adjusting nutrients and growth factors in continuous fermentation processes, as well as techniques for maximizing the rate of product formation, are well known in the art of industrial microbiology.

[0156] Cultivation / fermentation is generally carried out in a growth medium comprising an aqueous inorganic salts medium, organic growth factors, carbon and energy source materials, molecular oxygen, and, of course, a starting inoculum of the microbial host being used.

[0157] To ensure proper microbial growth, maximize the uptake of carbon and energy sources by the cells in the microbial conversion process, and achieve maximum cell yield at maximum cell density in the fermentation medium, suitable amounts of inorganic nutrients must be supplied in appropriate proportions in addition to the carbon and energy sources, oxygen, assimilable nitrogen, and microbial inoculum.

[0158] The composition of the aqueous mineral medium can vary widely depending in part on the microorganism and substrate used, as is known in the art. In addition to nitrogen, the mineral medium will contain suitable amounts of phosphorus, magnesium, calcium, potassium, sulfur, and sodium in suitable soluble, absorbable, ionic complex forms, and preferably also several trace elements such as copper, manganese, molybdenum, zinc, iron, boron, and iodine, also in suitable soluble, absorbable forms, all of which are known in the art.

[0159] Fermentation reactions are aerobic processes in which the necessary molecular oxygen is supplied by a molecular oxygen-containing gas, such as air, oxygen-enriched air, or substantially pure molecular oxygen, provided to maintain the contents of the fermenter at a suitable oxygen partial pressure effective to support vigorous growth of the microbial species.

[0160] Fermentation temperatures can vary somewhat, but for most microbial cells the temperature will generally be in the range of about 20°C to 40°C.

[0161] Microorganisms also require an assimilable nitrogen source. The assimilable nitrogen source can be any nitrogen-containing compound or any compound that can release nitrogen in a form suitable for metabolic utilization by the microorganism. A variety of organic nitrogen source compounds, such as protein hydrolysates, can be used, but typically inexpensive nitrogen-containing compounds such as ammonia, ammonium hydroxide, urea, and various ammonium salts such as ammonium phosphate, ammonium sulfate, ammonium pyrophosphate, ammonium chloride, or various other ammonium compounds can be utilized. Ammonia gas itself is convenient for large-scale operations and can be used by bubbling the aqueous fermentation product (fermentation medium) in a suitable amount. At the same time, such ammonia can also be used to aid in pH control.

[0162] The pH range of the aqueous microbial fermentation (fermentation mixture) should be in the exemplary range of about 2.0 to 8.0 The preferred pH range of a microorganism will depend to some extent on the medium and the particular microorganism used, and will therefore vary somewhat with changes in medium, as can be readily determined by one of skill in the art.

[0163] It is preferred to carry out the fermentation in such a way that it is possible to control the carbon-containing substrate as the limiting factor, thereby providing good conversion of the carbon-containing substrate to the cells and avoiding contamination of the cells with significant amounts of unconverted substrate. The latter is not a problem with water-soluble substrates, since traces of residues can be easily washed away. However, it can be a problem with water-insoluble substrates, necessitating additional product processing steps, such as suitable washing steps.

[0164] As noted above, the time to reach this level is not critical and may vary depending on the particular microorganism and fermentation process being carried out, however, methods for determining the carbon source concentration in a fermentation medium and whether a desired carbon source level has been achieved are well known in the art.

[0165] If necessary, some or all of the carbon and energy source materials and / or a portion of the assimilable nitrogen source, such as ammonia, can be added to the aqueous mineral medium before it is fed to the fermenter.

[0166] Each of the streams introduced into the reactor is preferably controlled at a predetermined rate or according to needs that can be determined by monitoring the concentrations of carbon and energy substrates, pH, dissolved oxygen, oxygen or carbon dioxide in the fermenter exhaust gas, cell density as measured by dry cell weight, light transmittance, etc. The feed rates of the various materials can be varied in order to obtain the fastest possible cell growth rate and the highest possible yield of microbial cells relative to the substrate feed, consistent with efficient utilization of the carbon and energy sources.

[0167] In a batch or, preferably, fed-batch operation, all equipment, reactors, or fermentation means, tanks or vessels, piping, associated circulation or cooling devices, etc. are first sterilized, usually using steam, for example, at about 121° C. for at least about 15 minutes. The sterilized reactor is then inoculated with a culture of the selected microorganism in the presence of all necessary nutrients, including oxygen, and a carbon-containing substrate. The type of fermenter used is not critical.

[0168] V. Protein of interest The protein of interest (POI) may be any endogenous or heterologous protein, or may be a variant of such a POI. The protein may contain one or more disulfide bridges, or may be a protein whose functional form is monomeric or multimeric (i.e., the protein has a quaternary (4°) structure and is composed of multiple identical (homologous) or non-identical (heterologous) subunits). In certain aspects, the recombinant cells of the present disclosure express / produce one or more endogenous proteins of interest, one or more heterologous proteins of interest, a combination thereof, etc.

[0169] In certain embodiments, the modified cells can produce an increased amount of POI compared to the parental (or control) cells, the increased amount of POI being at least about 0.01% increase, at least about 0.10% increase, at least about 0.50% increase, at least about 1.0% increase, at least about 2.0% increase, at least about 3.0% increase, at least about 4.0% increase, at least about 5.0% increase, or more than 5.0% increase. In certain aspects, the increased amount of POI is determined by assaying enzyme activity, by assaying protein function, by assaying / quantifying specific productivity (Qp), etc. For example, one skilled in the art can utilize routine methods and techniques known in the art for detecting, assaying, measuring, etc., protein expression, production, secretion, etc.

[0170] In certain embodiments, the POI or variant POI thereof is an enzyme. In certain aspects, the enzyme is an acetyl esterase, an aminopeptidase, an amylase, an arabinase, an arabinofuranosidase, an aryl esterase, a carbonic anhydrase, a carboxypeptidase, a catalase, a cellulase, a chitinase, a chymosin, a cutinase, a deoxyribonuclease, an epimerase, an esterase, an α-galactosidase, a β-galactosidase, an α-glucanase, a glucan lyase, an endo-β-glucanase, a glucoamylase, a glucose oxidase, an α-glucosidase, a β-glucosidase, a glucuronidase, a glycosyl hydrolase, a hemicellulase, a hexose oxidase, a hydrolase, an invertase, an isomer ... In some embodiments, the enzyme is selected from the group consisting of enzymes, laccases, ligases, lipases, lyases, lysozymes, mannosidases, oxidases, oxidoreductases, pectate lyases, pectin acetyl esterases, pectin depolymerases, pectin methyl esterases, pectinolytic enzymes, perhydrolases, polyol oxidases, peroxidases, phenol oxidases, phosphodiesterases, phytases, polyesterases, polygalacturonases, proteases, peptidases, rhamnogalacturonase, ribonucleases, transferases, transport proteins, transglutaminase, xylanase, hexose oxidase, and combinations thereof.

[0171] In related aspects, the POI or variant POI is an enzyme selected from the Enzyme Commission (EC) Numbers: EC1, EC2, EC3, EC4, EC5, or EC6. For example, in certain embodiments, the POI is an oxidoreductase enzyme. In other embodiments, the POI is a transferase enzyme. In other embodiments, the POI is a hydrolase enzyme. In other embodiments, the POI is a lyase enzyme. In certain other embodiments, the POI is an isomerase enzyme. In yet other embodiments, the POI is a ligase enzyme.

[0172] In certain aspects, the enzymes are proteases (e.g., neutral proteases, metalloproteases) and alkaline (or "serine") proteases. For example, Bacillus subtilisin proteins (enzymes) are exemplary serine proteases used in the present disclosure. A wide variety of Bacillus subtilisins have been identified and sequenced, such as subtilisin 168, subtilisin BPN', subtilisin Carlsberg, subtilisin DY, subtilisin 147, and subtilisin 309. In some embodiments of the present disclosure, the engineered Bacillus cells produce mutant (i.e., variant) proteases. Thus, in certain embodiments, the engineered Bacillus cells comprise an expression construct encoding a protease. In certain other embodiments, the altered Bacillus cell comprises an expression construct encoding an amylase. A wide variety of amylase enzymes and variants thereof are known to those of skill in the art.

[0173] In other embodiments, the POI or variant POI expressed and produced in the engineered cells is a peptide, peptide hormone, growth factor, coagulation factor, chemokine, cytokine, lymphokine, antibody, receptor, adhesion molecule, microbial antigen (e.g., HBV surface antigen, HPV E7, etc.), and variants, fragments thereof, etc. Other types of proteins of interest (or variants thereof) can be proteins that can provide nutritional value to food or crops. Non-limiting examples include plant proteins that can inhibit the formation of anti-nutritional factors and plant proteins that have a more desirable amino acid composition (e.g., higher lysine content than non-transgenic plants).

[0174] As briefly mentioned above, there are various assays known to those skilled in the art for detecting and measuring the activity of intracellularly and extracellularly expressed proteins. In particular, for proteases, there are assays based on the release of acid-soluble peptides from casein or hemoglobin, measured as absorbance at 280 nm or colorimetrically using the Folin method. Other exemplary assays include the Succinyl-Ala-Ala-Pro-Phe-para-nitroanilide assay (SAAPFpNA) and the 2,4,6-trinitrobenzenesulfonic acid sodium salt assay (TNBS assay). WO 2014 / 164777 discloses a Ceralpha α-amylase activity assay useful for amylase activity as described herein. Means for determining the secretion level of a protein of interest in a host cell and for detecting expressed proteins include the use of immunoassays using either polyclonal or monoclonal antibodies specific for the protein. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), fluorescent immunoassay (FIA) and fluorescence activated cell sorting (FACS).

[0175] VI. ILLUSTRATIVE EMBODIMENTS Non-limiting embodiments of the compositions and methods disclosed herein are as follows.

[0176] 1. The prsA gene cassette integrated at the amyL locus of Bacillus licheniformis cells.

[0177] 2. A cassette as described in embodiment 1, comprising an upstream (5') prsA gene promoter sequence operably linked to a downstream (3') prsA gene coding sequence (CDS).

[0178] 3. The cassette of embodiment 2, wherein the prsA gene promoter sequence comprises at least 85% identity to SEQ ID NO:29.

[0179] 4. The cassette of embodiment 2, wherein the prsA gene CDS comprises at least 80% identity to SEQ ID NO:30.

[0180] 5. A recombinant Bacillus licheniformis cell producing a protein of interest (POI) and containing the prsA gene cassette integrated at the amyL locus.

[0181] 6. The recombinant cell of embodiment 5, which produces an increased amount of a POI compared to a control Bacillus cell producing the same POI, wherein the control cell contains the same prsA gene cassette integrated at the catH locus.

[0182] 7. The recombinant cell of embodiment 5, which produces an increased amount of a POI compared to a control Bacillus cell producing the same POI, wherein the control cell comprises a non-integrated prsA gene cassette.

[0183] 8. The recombinant cell of embodiment 5, wherein the cassette comprises a prsA gene coding sequence (CDS) comprising at least 80% identity to SEQ ID NO:30.

[0184] 9. The recombinant cell of embodiment 5, wherein the cassette comprises a promoter sequence comprising at least 85% identity to SEQ ID NO:29.

[0185] 10. A recombinant cell according to embodiment 5, wherein the POI is an enzyme.

[0186] 11. A method for producing a protein of interest (POI) in a Bacillus licheniformis cell, comprising obtaining or constructing a Bacillus cell that produces the POI, introducing into the cell a prsA gene cassette integrated at the amyL locus, and fermenting the recombinant cell under conditions suitable for production of the POI.

[0187] 12. The method of embodiment 11, wherein the recombinant cells produce an increased amount of the POI compared to control B. licheniformis cells producing the same POI, the control cells containing the same prsA gene cassette integrated at the catH locus.

[0188] 13. The method of embodiment 11, wherein the recombinant cells produce an increased amount of the POI compared to control B. licheniformis cells producing the same POI, the control cells comprising a non-integrated prsA gene cassette.

[0189] 14. The method of embodiment 11, wherein the cassette comprises a prsA gene coding sequence (CDS) comprising at least 80% identity to SEQ ID NO:30.

[0190] 15. The method of embodiment 11, wherein the cassette comprises a promoter sequence comprising at least 85% identity to SEQ ID NO:29.

[0191] 16. The method of embodiment 11, wherein the POI is an enzyme. EXAMPLES

[0192] Certain aspects of the present invention can be further understood in light of the following examples, which should not be construed as limiting. Modifications of materials and methods will be apparent to those skilled in the art. Standard recombinant DNA and molecular cloning techniques used herein are well known in the art (Ausubel et al., 1987; Sambrook et al., 1989). As described herein, all expression cassettes were transformed into host strains using the methods described in WO2019 / 040412 (incorporated herein by reference in its entirety).

[0193] Example 1 Construction of plasmid pRF1005 targeting the catH locus In this example, a Cas9 plasmid pRF1005 targeting the catH locus was constructed, which contains the editing template (SEQ ID NO: 11). The plasmid backbone was amplified by PCR from pRF946 described in WO2021 / 146411 (incorporated by reference in its entirety) using primers 860 (SEQ ID NO: 1; Table 2) and 861 (SEQ ID NO: 2; Table 2), and the editing template insert was amplified by PCR from a synthetic template using primers 1636 (SEQ ID NO: 3; Table 2) and 1637 (SEQ ID NO: 4; Table 2). The two parts were assembled and transformed into E. coli using NEBuilder according to the manufacturer's instructions. A sequence-confirmed isolate was saved as pRF1005 (SEQ ID NO: 12). Plasmid pRF1005 was used to delete the catH gene at the amyL locus. Plasmids were amplified using rolling circle amplification (RCA) to make them suitable substrates for transformation using the TempliPhi amplification kit (GE Healthcare). [Table 2]

[0194] Example 2 Construction of engineered host strains The recombinant B. licheniformis strains described herein can be constructed by one of skill in the art using any suitable B. licheniformis host (see, e.g., WO 2019 / 40412 and WO 2021 / 146411; each of which is incorporated by reference in its entirety). For example, in certain aspects, host modifications can be introduced into a B. licheniformis strain, such as BF140 (ΔserA1_ΔlysA), which contains deletions of serA1 and lysA, as generally described in WO 2019 / 40412. In other aspects, the host modifications can be introduced into a B. licheniformis strain (e.g., BF140) that further comprises one or more genetic modifications, including, but not limited to, a modified dltA gene and / or a modified rghR2 gene, as generally described in WO 2021 / 146411.

[0195] In this example, a series of host modifications were introduced into the parent B. licheniformis strain BF140, which contains deletions of the serA1 (SEQ ID NO: 13) and lysA genes (SEQ ID NO: 14) and contains the pBl.comK plasmid (SEQ ID NO: 15), as described in WO 2019 / 40412. More specifically, a deleted rghR2 (ΔrghR2) allele was first constructed in the BF140 strain, as described in WO 2021 / 146411. Briefly, a variant of BF140 containing the pBl.comK plasmid (SEQ ID NO: 15) was made competent (WO 2021 / 146411). 100 μl of competent cells were mixed with 5 μl of pRF879 (SEQ ID NO: 78; WO 2021 / 146411) RCA and incubated at 1400 RPM and 37° C. for 1.5 hours. The mixture was plated on L agar plates containing 20 ppm kanamycin to select for cells transformed with the plasmid. Colonies were screened for the ΔrghR2 allele (SEQ ID NO: 16), a deletion of the rghR2 coding sequence except for the first 9 bp and the last 9 bp, using standard PCR techniques and the primers in Table 3 below. Colonies carrying the ΔrghR2 allele (SEQ ID NO: 16) produce a 1523 bp PCR product (SEQ ID NO: 17) using the forward primer (SEQ ID NO: 5) and reverse primer (SEQ ID NO: 6) described in Table 3 below, while parental cells containing an intact rhgR2 gene produce a 1922 bp PCR product (SEQ ID NO: 18). The colony containing the ΔrghR2 allele was saved as BF412. [Table 3]

[0196] A variant of BF412 containing the pBl.comK plasmid (SEQ ID NO: 15) was made competent (WO 2021 / 146411). 100 μl of competent cells were mixed with 5 μl of pZM221 (SEQ ID NO: 84; WO 2021146411) RCA and incubated at 1400 RPM and 37° C. for 1.5 hours. The mixture was plated on L agar plates containing 20 ppm kanamycin. Colonies were screened for the ΔdltA-2 allele (SEQ ID NO: 19), a 700 bp deletion of the dltA coding sequence, using standard PCR techniques and the forward primer (SEQ ID NO: 7) and reverse primer (SEQ ID NO: 8) described in Table 4 below. Colonies carrying the ΔdltA-2 allele produce a 2067 bp PCR product (SEQ ID NO:20) using the primers in Table 4, while parental cells containing an intact dltA gene produce a 2767 bp PCR product (SEQ ID NO:21), which can be distinguished using standard electrophoretic techniques. A colony containing a 700 bp internal deletion of dltA (SEQ ID NO:19) was saved as BF772. [Table 4]

[0197] A variant of strain BF772 containing the pBl.comK plasmid (SEQ ID NO: 15) was made competent (WO 2021 / 146411) and transformed with the prsA gene ( ndThe vector was transformed with a linear PCR product targeting the amyL locus for integration of the B. subtilis CatH gene (SEQ ID NO:22) copy. For example, the targeting construct (cassette) comprises an upstream (5') homology arm (SEQ ID NO:23) to the amyL locus operably linked to the catH promoter (SEQ ID NO:24), operably linked to DNA encoding the CatH protein (SEQ ID NO:25), operably linked to a dual terminator (SEQ ID NO:26) composed of the CatH terminator (SEQ ID NO:27) operably linked to the spoVG terminator of B. subtilis (SEQ ID NO:28). The construct further comprises the B. licheniformis prsA promoter (SEQ ID NO:29) operably linked to the B. licheniformis prsA CDS (SEQ ID NO:30), operably linked to a terminator from the amyL gene of B. licheniformis (SEQ ID NO:31), which is operably linked to a downstream homology arm (SEQ ID NO:32) to the amyL locus.

[0198] Colonies that formed on L agar containing 10 ppm chloramphenicol were screened using colony PCR to confirm modification of the amyL locus using standard PCR techniques with the forward primer (SEQ ID NO: 9) and reverse primer (SEQ ID NO: 10) described in Table 5 below. A colony containing the integrated cassette (SEQ ID NO: 33) at the amyL locus produced a PCR product of 3562 bp. The PCR product (SEQ ID NO: 35) was sequenced using the Sanger method and the isolate was archived as ZM1319. [Table 5]

[0199] A variant of ZM1319 containing the pBl.comK plasmid (SEQ ID NO: 15) was made competent (WO 2021 / 146411). 100 μl of competent cells were mixed with 5 μl of pRF1005 RCA and incubated at 1400 RPM and 37° C. for 1.5 hours. The mixture was plated on L agar plates containing 20 ppm kanamycin. Using standard PCR techniques and the forward primer (SEQ ID NO: 9) and reverse primer (SEQ ID NO: 10) described in Table 5, colonies were screened for the deletion of the DNA encoding the 3' end of the catH promoter (SEQ ID NO: 24) and the DNA sequence encoding the CatH protein (SEQ ID NO: 25) while maintaining the amyL::prsAp-prsA cassette (SEQ ID NO: 33).

[0200] Integrated at the amyL locus (2 nd A correct colony containing the amyL::prsAp-prsA cassette (SEQ ID NO: 33) produced a PCR product of 2698 bp (SEQ ID NO: 34), in contrast to the one integrated at the catH locus (2 copies). nd The parent colony containing the amyL::catH-prsAp-prsA cassette (SEQ ID NO:22) produced a PCR product 3562 bp in length (SEQ ID NO:35). This difference was assessed visually using standard gel electrophoresis techniques and by sequencing the PCR product using the Sanger method. The isolate was archived as ZM1322.

[0201] A variant of ZM1322, designated ZM1325, containing the pBl.comK plasmid (SEQ ID NO: 15) was used in the following examples as a host strain for amylase reporter production. The ZM1325 strain was introduced (2 nd It contains the same host modifications as the previously described host strain BF613 (WO 2021 / 146411), except that a (2 copy) prsA cassette has been integrated at the amyL locus in the ZM1325 strain, while the same introduced (2 copies) prsA cassette has been integrated at the amyL locus in the ZM1325 strain. ndA (copy) prsA cassette was integrated at the catH locus in the BF613 strain.

[0202] Example 3 Enhanced amylase 1 production in Bacillus cells containing a second copy prsA gene integrated at the amyL locus In this example, an expression cassette encoding a variant α-amylase (herein, "amylase 1," abbreviated as "Amy1") was introduced into B. licheniformis strains BF613 and ZM1325 (i.e., containing deletions of the serA1 and lysA genes). More specifically, strain BF613 contained the introduced (2 nd ZM1325 contained the same introduced (2 copies) prsA expression cassette integrated at the amyL locus. nd BF613 and ZM1325 are isogenic strains except that they contain a (copy)prsA expression cassette.

[0203] For example, the first (1 st The serA1 locus is integrated with a synthetic p3 promoter (SEQ ID NO:37) operably linked to the serA1 ORF (SEQ ID NO:13), operably linked to the B. licheniformis amyL transcription terminator (SEQ ID NO:40), operably linked to DNA encoding Amy1 (SEQ ID NO:36), operably linked to DNA encoding the B. licheniformis Amyl signal peptide sequence (SEQ ID NO:39), operably linked to a modified B. subtilis aprE 5'-UTR (SEQ ID NO:38). nd) cassette integrated into the lysA locus and contains the lysA ORF (SEQ ID NO: 14) and the B. licheniformis p2 promoter (SEQ ID NO: 41), operably linked to the modified B. subtilis aprE 5'-UTR (SEQ ID NO: 38), operably linked to DNA encoding Amy1 (SEQ ID NO: 36), operably linked to DNA encoding the B. licheniformis AmyL signal peptide sequence (SEQ ID NO: 39), operably linked to the B. licheniformis amyL transcription terminator (SEQ ID NO: 40). This resulted in Amy1-producing strains designated LDN665 (i.e., strain BF613 carrying two copies of Amy1 at the lysA and serA loci) and ZM1351 (i.e., strain ZM1325 carrying two copies of Amy1 at the lysA and serA loci).

[0204] The two Amy1 producing strains (LDN665 and ZM1351) were assayed for α-amylase production using standard small-scale conditions (as described in WO 2018 / 156705 and WO 2019 / 055261, each of which is incorporated herein by reference). For example, the amylase reporter protein produced (Amy1) was quantified using the Bradford method or the Ceralpha assay, and the results of this assay are shown in Table 6, which shows the results of the expression of the prsA gene integrated at the amyL locus (LDN665) instead of the catH locus (2 nd They demonstrate improved Amy1 production in a strain (ZM1351) containing the 1.2 copies of Amy1. [Table 6]

[0205] Example 4 Enhanced amylase 2 production in Bacillus cells containing a second copy prsA gene integrated at the amyL locus In this embodiment, an expression cassette encoding a different amylase reporter protein [Triple-A 21508-1] (herein "Amylase 2", abbreviated "Amy2") was introduced into B. licheniformis strains BF613 and ZM1325 (i.e., containing deletions of the serA1 and lysA genes). As described above, strain BF613 contained the introduced (2 nd ZM1325 contained the same introduced (2 copies) prsA expression cassette integrated at the amyL locus. nd BF613 and ZM1325 are isogenic strains, except that they contain the first (1 copy) prsA expression cassette of Amy2 (SEQ ID NO: 42). st A serA1 ORF (SEQ ID NO: 13) operably linked to a synthetic p3 promoter (SEQ ID NO: 37), operably linked to a modified B. subtilis aprE 5'-UTR (SEQ ID NO: 38), operably linked to DNA encoding Amy2 (SEQ ID NO: 42), operably linked to DNA encoding the B. licheniformis AmyL signal peptide sequence (SEQ ID NO: 39), operably linked to a B. licheniformis amyL transcription terminator (SEQ ID NO: 40). nd) cassette integrated into the lysA locus and contains the lysA ORF (SEQ ID NO: 14) and the B. licheniformis p2 promoter (SEQ ID NO: 41) operably linked to a modified B. subtilis aprE 5'-UTR (SEQ ID NO: 38), operably linked to DNA encoding Amy2 (SEQ ID NO: 42), operably linked to DNA encoding the B. licheniformis AmyL signal peptide sequence (SEQ ID NO: 39), operably linked to the B. licheniformis amyL transcription terminator (SEQ ID NO: 40). This resulted in Amy2-producing strains designated WAAA57 (i.e., strain BF613 harboring two copies of Amy2 at the lysA and serA loci) and WAAA197 (i.e., strain ZM1325 harboring two copies of Amy1 at the lysA and serA loci).

[0206] Two Amy2-producing strains (WAAA57 and WAAA197) were assayed for amylase production (using the standard small-scale conditions described in Example 3) and the results of the reporter assay are shown in Table 7, which show that the introduction of the prsA gene integrated at the amyL locus (WAAA57) instead of the catH locus (WAAA197) was significantly associated with amylase production. nd The results demonstrate improved Amy2 production in a strain (WAAA197) containing the .ALPHA.-Amy2 gene (T1 copy). [Table 7]

[0207] References International Publication No. 1994 / 19471 Brochure International Publication No. 2002 / 14490 Brochure International Publication No. 2003 / 083125 Brochure International Publication No. 2003 / 089604 Brochure International Publication No. 2019 / 40412 Brochure International Publication No. 2021 / 146411 Brochure International Publication No. 2014 / 164777 Brochure US Patent Publication No. 20100255534 Caspers et al., “Improvement of Sec-dependent secretion of a heterologous model protein in Bacillus subtilis by saturation mutagenesis of the N-domain of the AmyE signal peptide”, Appl.Microbiol.Biotechnol., 86(6):1877-1885, 2010. Castillo-Hair et al., “An Engineered B. subtilis Inducible Promoter System with over 10 000-Fold Dynamic Range”, ACS Synth. Biol., 8(7):1673-1678, 2019. Earl et al., “Ecology and genomics of Bacillus subtilis”, Trends in Microbiology., 16(6):269-275, 2008. Kontinen and Sarvas, “Mutants of Bacillus subtilis Defective in Protein Export”, J. Gen. Microbiology, 134, pages 2333-2344, 1988. Kontinen et al., “A gene(prsA) of Bacillus subtilis involved in a novel, late stage of protein export”, Mol. Microbiology, 5, pages 1273-1283, 1991. Olempska-Beer et al.,“Food-processing enzymes from recombinant microorganisms--a review”’ Regul.Toxicol.Pharmacol.,45(2):144-158、2006. Van Dijl and Hecker,“Bacillus subtilis:from soil bacterium to super-secreting cell factory”,Microbial Cell Factories,12(3).2013. Wang et al.,“Engineering strong and stress-responsive promoters in Bacillus subtilis by interlocking sigma factor binding motifs”,Synth.Syst.Biotechnol.,4(4):197-203,2019. Zhou et al.,“Promoter engineering enables overproduction of foreign proteins from a single copy expression cassette in Bacillus subtilis”,Microbial Cell Factories,18(111),2019.

Claims

1. The prsA gene cassette integrated at the amyL locus of Bacillus licheniformis cells.

2. 2. The cassette of claim 1, comprising an upstream (5') prsA gene promoter sequence operably linked to a downstream (3') prsA gene coding sequence (CDS).

3. The cassette of claim 2 , wherein the prsA gene promoter sequence comprises at least 85% identity to SEQ ID NO:

29.

4. The cassette of claim 2 , wherein the prsA gene CDS comprises at least 80% identity to SEQ ID NO:

30.

5. A recombinant Bacillus licheniformis cell producing a protein of interest (POI) and containing an integrated prsA gene cassette at the amyL locus.

6. 6. The recombinant cell of claim 5, which produces an increased amount of said POI compared to a control Bacillus cell producing the same POI, said control cell containing the same prsA gene cassette integrated at the catH locus.

7. 6. The recombinant cell of claim 5, which produces an increased amount of said POI compared to a control Bacillus cell producing the same POI, said control cell containing an introduced non-integrated copy of the same prsA gene cassette.

8. The recombinant cell of claim 5, wherein the cassette comprises a prsA gene coding sequence (CDS) that comprises at least 80% identity to SEQ ID NO:

30.

9. The recombinant cell of claim 5, wherein the cassette comprises a promoter sequence comprising at least 85% identity to SEQ ID NO:

29.

10. The recombinant cell of claim 5 , wherein the POI is an enzyme.

11. A method for producing a protein of interest (POI) in a Bacillus licheniformis cell, comprising obtaining or constructing a POI-producing B. licheniformis cell, introducing into said cell a prsA gene cassette integrated at the amyL locus, and fermenting said recombinant cell under conditions suitable for the production of said POI.

12. 12. The method of claim 11, wherein the recombinant cells produce an increased amount of the POI compared to a control B. licheniformis cell producing the same POI, the control cell comprising the same prsA gene cassette integrated at the catH locus.

13. 12. The method of claim 11, wherein the recombinant cells produce an increased amount of the POI compared to a control B. licheniformis cell producing the same POI, the control cell comprising an introduced, non-integrated copy of the same prsA gene cassette.

14. The method of claim 11, wherein the cassette comprises a prsA gene coding sequence (CDS) that comprises at least 80% identity to SEQ ID NO:

30.

15. The method of claim 11, wherein the cassette comprises a prsA gene promoter sequence comprising at least 85% identity to SEQ ID NO:

29.

16. The method of claim 11 , wherein the POI is an enzyme.

Citation Information

Patent Citations

  • Cognate foldase co-expression

    WO2020156903A1

  • Compositions and methods for increased protein production in bacillus licheniformis

    WO2021030267A1

  • Compositions and methods for enhanced protein production in bacillus licheniformis

    WO2021146411A1